Valuation: Charles River Laboratories International, Inc.

Market Cap 1.37TCr 1.18TCr 1.11TCr 1.01TCr 1.9TCr 1,30900Cr 1.93TCr 13TCr 5.1TCr 66TCr 5.14TCr 5.03TCr 2,18400Cr P/E 2026 *
74.7x
P/E 2027 * 29.9x
Enterprise Value 1.58TCr 1.36TCr 1.28TCr 1.17TCr 2.2TCr 1,51100Cr 2.23TCr 15TCr 5.89TCr 76TCr 5.93TCr 5.8TCr 2,52200Cr EV / Sales 2026 *
4.04x
EV / Sales 2027 * 3.83x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week+6.40%
Current month+20.48%
1 month+24.10%
3 months+80.54%
6 months+81.81%
Current year+43.09%
1 week 240.9
Extreme 240.9
246.1
1 month 191.45
Extreme 191.45
246.1
Current year 127.95
Extreme 127.95
246.1
1 year 124.25
Extreme 124.25
246.1
3 years 87.7
Extreme 87.7
251.8
5 years 87.7
Extreme 87.7
388
10 years 59.83
Extreme 59.829
388
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%+6.40% - - 1.37TCr
-0.11%-2.38%+2.06%+19.57% 4.88TCr
+1.89%+4.36%+494.71%+637.45% 4.54TCr
+1.83%+2.83%+14.87%+91.99% 4.12TCr
-0.50%-0.81%+25.61%+12.05% 3.97TCr
-2.74%-2.74%+17.30%+56.10% 3.26TCr
+0.59%-2.65% - - 1.62TCr
-1.14%-2.01%+28.93%+132.78% 1.67TCr
-0.49%-0.54%+2.96%+27.12% 1.41TCr
-2.60%+0.79%+78.19%+39.69% 1.37TCr
Average -0.12%-0.78%+83.08%+127.09% 2.98TCr
Weighted average by Cap. +0.08%-0.84%+104.53%+155.24%

Financials

2026 *2027 *
Net sales 391.1Cr 337.9Cr 317.71Cr 289.04Cr 543.49Cr 37TCr 552.04Cr 3.73TCr 1.46TCr 19TCr 1.47TCr 1.44TCr 62TCr 400.08Cr 345.65Cr 325Cr 295.67Cr 555.96Cr 38TCr 564.71Cr 3.81TCr 1.49TCr 19TCr 1.5TCr 1.47TCr 64TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 154.83Cr 61Cr 778.53Cr 61Cr 60Cr 2.59TCr 43Cr 37Cr 35Cr 32Cr 59Cr 4.09TCr 60Cr 407.66Cr 159.55Cr 2.05TCr 160.6Cr 157.1Cr 6.83TCr
Net Debt 211.22Cr 182.49Cr 171.59Cr 156.1Cr 293.52Cr 20TCr 298.14Cr 2.01TCr 787.79Cr 10TCr 793.02Cr 775.7Cr 34TCr 163.07Cr 140.88Cr 132.47Cr 120.51Cr 226.6Cr 16TCr 230.17Cr 1.55TCr 608.19Cr 7.81TCr 612.23Cr 598.85Cr 26TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
18/26/18 €245.90 +2.08%
17/26/17 €240.90 -1.51%
14/26/14 €244.60 -0.61%
13/26/13 €246.10 +1.03%
12/26/12 €243.60 +1.80%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
279.19USD
Average target price
281.00USD
Spread / Average Target
+0.65%

Quarterly revenue - Rate of surprise